contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


raysearch-laboratories-raysearch-releases-raystation-2023b

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

RaySearch Laboratories operates in the medical technology industry and focuses on the development and manufacture of software for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The operations are international and target customers globally. Laboratories was founded in 2000 and is headquartered in Stockholm, Sweden.

Raysearch Laboratories

RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2023B, the latest version of the company's comprehensive oncology treatment planning system. Version 2023B offers innovative...

<div class="abstract">RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2023B, the latest version of the company's comprehensive oncology treatment planning system. Version 2023B offers innovative new features in addition to multiple general enhancements.</div>Radiation therapy becomes more and more tailored to each patient with highly conformal dose delivery to the tumor and reduced exposure of normal tissue. More precise treatment plans require a higher level of follow-up throughout the course of treatment to ensure that the planned dose stays on track, as well as possibilities to adapt the plan if deviations are found. RaySearch has conducted research within adaptive replanning for two decades and when entering the field of treatment planning with RayStation, the system was designed from start with dose tracking and adaptive replanning in mind. RayStation 2023B takes the next steps and improves the workflows for dose tracking and replanning further.RayStation 2023B also comes with two innovative features within particle therapy: support for discrete proton arcs and robust optimization based on linear energy transfer (LET). LET optimization can be used in proton and ion therapy to lower LET in risk organs, which could reduce potential side effects of radiotherapy. Additionally, for treatments with heavy ions, such as carbon ions, particles with high LET can be focused inside the tumor, increasing the probability of tumor control.Discrete proton arc optimization provides tools to create plans with many more beam angles, which results in more conformal dose distributions and less dose to risk organs than conventional proton plans. RayStation supports a one-click conversion into regular pencil-beam scanning plans to be delivered by any existing pencil-beam scanning proton treatment machine. With this development, RayStation brings proton arc advances to existing proton facilities.Other highlights of RayStation 2023B include support for automatic field-in-field planning for photons, a method that generates homogeneous and conformal dose distributions by combining a few subfields, as well as point-based optimization of brachy plans, and faster loading of data.RayStation in combination with RayCare adds support for automated task management for all the steps in the planning workflow and ensures the user always has the right information at the right place. With the combination of RayStation 2023B and RayCare 2023B all necessary treatment plan information is available in RayCare when selecting which plan to deliver at a certain fraction.Johan Löf, founder and CEO, RaySearch, says: "With RayStation 2023B we show our strong dedication in providing world-class solutions for treatment planning. Adaptive replanning and high-level of integration of different systems at the clinic will pave the way towards personalized treatments and improved patient care."